Latest News
ASCO and EHA highlights in myeloma and AL amyloidosis
The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual…
FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patients
Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020.
MPE webinar on the impact of myeloma and AL amyloidosis in carers. What are the issues and challenges?
Myeloma Patients Europe (MPE) will hold a webinar on the impact of myeloma and AL amyloidosis in carers on Wednesday 20 May 2020 from 18:00 – 19:00 CET. The webinar will be given by Ellen Watters, Myeloma Information Nurse Specialist at Myeloma UK (MUK), who will give a 40-minute presentation followed by a 20-minute…
MPE webinar on personalised medicines in myeloma and AL amyloidosis
Myeloma Patients Europe (MPE) will hold a webinar on personalised medicines in myeloma and AL amyloidosis on Wednesday 6 May 2020 from 18:00 – 19:00 CET.
- MO
- TU
- WE
- TH
- FR
- SA
- SU
- 23
- 24
- 25
- 26
- 27
- 28
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 1
- 2
- 3
- 4
- 5